Perspectives on the development of a molecularly targeted agent

Research output: Contribution to journalArticle

232 Scopus citations

Abstract

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalCancer Cell
Volume1
Issue number1
DOIs
Publication statusPublished - Feb 2002

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this